Amarin Corp Plc (AMRN)

[IslandOfMisfitToys]

Rose, there are reasons to be skeptical about rosy estimates for Europe, because Europe won't tolerate the markups we see here in the US for drugs treating extra-nasty or rare diseases -- $50k a year being common and $1mm a year not unheard of.

But things are different for Vascepa. It's cheap, especially by US standards, and generally as well.

AND, remember that Vascepa was priced in the US reflecting the presence of generic Lovaza. JT has indicated that he expects European pricing, conservatively, to be the same as US pricing.

As is the case on many fronts, Amarin's situation is vastly different from the average biotech situation. Good and bad.